Analyst Price Targets — SPRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 16, 2026 10:40 am | Debjit Chattopadhyay | Guggenheim | $123.00 | $49.91 | TheFly | Spruce Biosciences initiated with a Buy at Guggenheim |
| June 1, 2026 10:08 am | — | H.C. Wainwright | $150.00 | $51.27 | TheFly | Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright |
| April 27, 2026 12:05 pm | Albert Lowe | Craig-Hallum | $140.00 | $55.63 | TheFly | Spruce Biosciences initiated with a Buy at Craig-Hallum |
| December 23, 2025 11:26 am | — | Oppenheimer | $283.00 | $82.82 | TheFly | Spruce Biosciences initiated with an Outperform at Oppenheimer |
| November 11, 2025 10:52 am | — | JMP Securities | $259.00 | $115.61 | TheFly | Spruce Biosciences price target raised to $259 from $254 at Citizens JMP |
| October 28, 2025 8:41 am | — | JMP Securities | $254.00 | $123.02 | TheFly | Spruce Biosciences upgraded to Outperform from Market Perform at Citizens JMP |
| October 21, 2025 6:38 pm | — | Leerink Partners | $160.00 | $134.00 | StreetInsider | Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink PartnersMember Login |
Latest News for SPRB
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a…
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable normalization of key biomarkers and stabilization of cognitive and motor function over six years, supporting its accelerated approval pathway. SPRB is preparing a BLA submission in Q4, with FDA feedback suggesting…
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological diso
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka “AJ” Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. “We are delighted to welcome AJ to the Spruce executive…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRB.
U.S. House Trading
No House trades found for SPRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.